Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

5 articles from the last 30 days matching "aging"

Clinical trialRSSToday

AAN 2026: Tavapadon helps delay levodopa start in early Parkinson’s

A new experimental drug called tavapadon from AbbVie helped people with early Parkinson's disease delay or avoid starting levodopa, which is the standard treatment for this condition. In a completed Phase 3 trial called TEMPO-4, most people taking tavapadon long-term did not need to start levodopa, and those already taking it didn't need to increase their dose. This suggests tavapadon could be a helpful new option for managing early Parkinson's symptoms.

WHY IT MATTERSIf approved, tavapadon could allow people with early Parkinson's to delay levodopa therapy, potentially postponing side effects that come with long-term use of this standard medication.
💬 Ask your doctorParkinson's diseaseRead →
Clinical trialCLINICALTRIALSApr 15

Trial Now Recruiting: IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens (NCT07074015)

Researchers are testing a new AI-powered tool called IntelliWell that can find sperm cells in testicular tissue samples that appeared to have no sperm when checked the traditional way. If the tool successfully finds sperm, those cells could be used to help men with infertility have biological children through a procedure called ICSI. The study is enrolling 20 participants at Brigham and Women's Hospital.

WHY IT MATTERSFor men with azoospermia (no sperm in ejaculate) who were told their testicular tissue had no usable sperm, this AI tool could recover sperm that was missed by standard testing, potentially making fertility treatment possible when it seemed impossible before.
You can act on thisazoospermiainfertilityRead →
Clinical trialUNITERAREApr 15

New Recruiting Trial: 18F-mFBG Cardiac Uptake With Lewy Body Dementia

Researchers are testing a new imaging scan called 18F-mFBG that can take pictures of the heart in people with Lewy body dementia, a brain disease that causes movement problems and thinking difficulties. This Phase 2 trial is now accepting patients and aims to see if this special scan can help doctors better understand and diagnose the disease. The scan uses a safe radioactive tracer that shows how well the heart's nerve endings are working.

WHY IT MATTERSThis trial is now actively recruiting patients with Lewy body dementia — if you have this diagnosis, you may be eligible to participate in a study that could help develop better diagnostic tools for your condition.
You can act on thisLewy body dementiaRead →
Clinical trialUNITERAREApr 5

New Recruiting Trial: Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy

Researchers are looking for people with Down syndrome (Trisomy 21) to join a study about how their immune system works differently and ages over time. Some participants will have had their thymus gland removed, while others won't have, so scientists can compare how this affects immune health. The study will help doctors understand why people with Down syndrome often get more infections and have other immune-related health problems.

WHY IT MATTERSThis trial is now recruiting people with Down syndrome to help researchers understand immune system problems that affect this population — findings could lead to better treatments for infections and other immune conditions common in Trisomy 21.
You can act on thisTrisomy 21Down syndromeRead →
Clinical trialCLINICALTRIALSApr 1

Trial Now Recruiting: Optical Imaging in X-linked Disorders. (NCT06868979)

Researchers are looking for 88 people with Fragile X Syndrome or Creatine Transporter Deficiency to test a new imaging technology that can see how the brain works. Both of these are genetic conditions that affect how the brain develops and cause intellectual disability. This study might help doctors better understand and diagnose these conditions in the future.

WHY IT MATTERSThis trial is recruiting patients with two of the most common X-linked intellectual disability disorders and may provide a new diagnostic tool that could improve how these conditions are identified and monitored.
You can act on thisFragile X SyndromeCreatine Transporter DeficiencyRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases